



World Health
Organization

Sudan Ebolavirus Candidate Vaccines: What additional research should be conducted to advance the evaluation of these vaccines?









12 January 2023



R&DBlueprint

Powering research
to prevent epidemics

Vaccines ready for clinical testing in Uganda

Type of vaccine	Vaccine developer	Viruses targeted	No. of doses	Immunogenicity + safety in humans?	Efficacy against SUSD in animals? ¹
cAd3	Sabin Vaccine Institute + US NIH	Sudan ebolavirus	Single 	Yes 	Yes 
cAdOx1	University of Oxford	Sudan + Zaire ebolaviruses	Single 	Yes 	Yes 
rVSV _{SUSD}	Merck/IAVI	Sudan ebolavirus	Single 	No	Yes 

¹ Each vaccine incorporates the ebolavirus surface protein into a harmless adenovirus (Ad). Both vaccines can protect animals against a potentially lethal dose of the Sudan ebolavirus.

Status

1. Outbreak is now under control and there is no immediate opportunity to generate clinical efficacy data
2. It is of outmost importance to define best use of current investigational vaccines supply
3. Generation of evidence that could support the advancement of these vaccines in the inter-epidemic phase remains a critical area
4. Regulatory pathways to bring vaccines to authorization need to be explored
5. Public health considerations on use of current supply should be part of the overall discussion

Key Questions

1. How do we advance the **evaluation** of these vaccines?
2. What data do we need to generate to support **authorization**?
3. What data do we need to help with **policy/decisions** during deployment?